Categories: Wire Stories

Nanbu Bijin’s Junmai Sake and Liqueurs Now Registered as Non-GMO Project Verified!

Following Kosher and Vegan certifications, aiming to further expand overseas sales channels!

NINOHE, Japan–(BUSINESS WIRE)–On November 3, Nanbu Bijin Co., Ltd. (Headquarters: Ninohe City, Iwate; President: Kosuke Kuji), which exports sake to 54 countries and regions around the world, registered its Junmai Sake and liqueurs as products produced in compliance with the Non-GMO Project Standard. The term �GMO” refers to organisms that have undergone a process of genetic engineering.


Many consumers in the U.S. and other countries, which are our largest export markets, pay close attention to whether our products are registered as “Non-GMO” or not. We believe this Verification is very important for such people to choose our products.

Please watch the video of Mr. Kuji explaining “Non-GMO Project Verification”: https://youtu.be/vvgmXZ7Kp9A

Background to registration as “Non-GMO”

Today, there are vegetarians (including vegans) and Muslims (halal) and Jews (kosher) worldwide. The company has learned that there are various food restrictions around the world, and lack of understanding or slow responses to these restrictions, especially in foreign countries, can lead to a great deal of lost opportunities for consumption.

Therefore, Nanbu Bijin acquired kosher certification in 2013 and vegan certification in January 2019 (domestic: NPO VegeProject Japan, overseas: The Vegan Society). Of the approximately 30 varieties exported overseas, a total of 14 were registered for this year’s verification, including 11 types of Junmai Sake, which is particularly popular with North American consumers, and three liqueurs, such as Sugar Free Plum Liqueur Umeshu.

The company is planning to obtain verification in Europe and other countries in the future.

For a sake to obtain “Non-GMO” verification is very rare and significant, both in Japan and abroad.

There is a growing interest in Non-GMO Project Verified products and a worldwide trend toward adopting more natural lifestyles, and we will continue to respond to the needs of these times.

Company Profile

Name: NANBU BIJIN Co, LTD.

Headquarters: 13, Kamimachi, Fukuoka, Ninohe, Iwate

President: Kosuke Kuji

Foundation: 1902

URL: https://www.nanbubijin.co.jp/en/

Awards for NANBU BIJIN

At International Wine Challenge 2017, “NANBU BIJIN Tokubetsu Junmai (special Junmai-shu)” won the Champion Sake in sake category as the best sake in the world. In 2020, NANBU BIJIN won platinum award at Kura Master 2020 and many gold awards in London Sake Challenge, International Sake Challenge, Concours Mondial des Vins FEMINALISE.

Contacts

NANBU BIJIN Co, LTD.

PR: Tomoko Takiguchi

Email: info@greencreate.jp

Alex

Recent Posts

Arizona Sonoran Continues to Define Near Surface Mineralization at MainSpring

CASA GRANDE, Ariz. & TORONTO--(BUSINESS WIRE)--$ASCU #Arizona--Arizona Sonoran Copper Company Inc. (TSX:ASCU | OTCQX:ASCUF) (“ASCU”…

11 mins ago

KAYTUS Introduces KR1280V2 – a 1U Server with 32 E1.S SSDs, Boosting I/O Performance for LLM Training

The KR1280V2, a 1U 2-socket high-density server, is ideal for compute-intensive applications like high-performance computing…

12 mins ago

Ooredoo Qatar Extends Partnership With Netcracker for Revenue Management and Managed Services Across All Lines of Business

Middle Eastern Operator Will Continue Leveraging Netcracker’s Digital BSS Product Suite and Managed Services to…

13 mins ago

SCG International Partners with Buna Al Mamlaka to Propel Sustainable Construction Innovations in Saudi Arabia

BANGKOK, THAILAND - Media OutReach Newswire - 21 May 2024 - SCG International Corporation Co.,…

15 mins ago

Atom Bioscience Marks Gout Awareness Day with Video Detailing Risks of Hyperuricemia, the Cause of Gout

Chronic gout linked to serious conditions including heart and kidney disease Safe and effective treatments…

1 hour ago

HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions

Filing of a U.S. IND for HFG1 is scheduled for Q3/2024 HANGZHOU, China--(BUSINESS WIRE)--HighField Biopharmaceuticals,…

1 hour ago